CSPC Pharmaceutical Group Limited is one of China’s largest and most innovative pharmaceutical enterprises, engaged in the research, development, manufacturing, and distribution of both innovative and generic drugs. Headquartered in Shijiazhuang, Hebei Province, CSPC has built a vertically integrated operation with global reach, focusing on treatments for central nervous system (CNS) disorders, oncology, cardiovascular, anti-infectives, and metabolic diseases. ## Core Business CSPC operates across three primary business segments: - Finished Dosage Drugs: Covering innovative patented medicines, first-to-market generics, and essential medicines - Bulk Active Pharmaceutical Ingredients (APIs): Including vitamins, antibiotics, and caffeine derivatives - Functional Foods & Nutraceuticals: With offerings like vitamin C tablets, caffeine food additives, and metabolic health products The company is listed on the Hong Kong Stock Exchange (HKEX: 1093) and is recognized globally for its R&D capabilities and market-driven innovation. ## Product and Service Offerings ### Innovative Medicines - NBP (Butylphthalide Soft Capsules) – Used for stroke recovery; a Class 1.1 New Drug in China - Jinyouli (Pegfilgrastim Injection) – Biosimilar approved for neutropenia - Keaili (Irinotecan Liposome Injection) – Antitumor drug for pancreatic and gastric cancers - Xuanning (Levamlodipine) – A novel calcium channel blocker for hypertension - Domeisu (Imrecoxib) – A new generation COX-2 inhibitor for osteoarthritis ### Generic Drugs - Over 200 formulations including antibiotics, antivirals, cardiovascular and anti-diabetic treatments - Includes tablets, capsules, injections, powders, and oral solutions ### Bulk APIs - Vitamin C (one of the world’s largest manufacturers) - Caffeine & Theobromine - Antibiotic APIs: Amoxicillin, Ampicillin, Cefazolin, Cefalexin ### Nutraceuticals & Functional Ingredients - Vitamin C Tablets - Caffeine Food Additives - Acarbose (for blood sugar management) ## Specialization and Core USP CSPC’s unique strengths include: - Dual-core R&D strategy: 1) Innovative drug discovery via CSPC Zhongqi; 2) Generic and biosimilar platform via CSPC Ouyi and CSPC XNW - Pipeline of 300+ clinical candidates, with 40+ in Phase I–III clinical stages - Strong biosimilar and monoclonal antibody production capabilities - Over 1,000 patents granted globally - Global supplier of high-purity vitamin C and APIs ## Financials As of 2023 (audited): - Total Revenue: RMB 32.4 billion (~USD 4.5 billion) - Net Profit: RMB 6.1 billion (~USD 850 million) - R&D Investment: RMB 3.6 billion (~11.2% of revenue) - Market Cap: USD 13+ billion - Recognized among China’s Top 10 Pharmaceutical Companies for multiple consecutive years ## Shipment Records - Export Markets: Over 100 countries and regions across North America, EU, ASEAN, MENA, and LATAM - Top API Exported: Vitamin C, caffeine, and antibiotics - Certifications: EU-GMP, US FDA, WHO-PQ, Japanese PMDA, and Korean MFDS approvals for multiple facilities and products ## Target Market CSPC’s diverse client base includes: - Global pharmaceutical companies - API wholesalers and distributors - Hospital systems and government tender platforms - OTC and consumer health product manufacturers Product applications span: - Prescription & hospital-based therapies - Contract manufacturing (CMO/CDMO) - B2B ingredient supply - Retail pharmacy and e-commerce wellness markets ## Capabilities - R&D Institutes: Over 1,800 scientists across five major innovation centers in China and the US - Manufacturing Sites: 15+ cGMP-certified facilities across Hebei, Shandong, Jiangsu, and Zhejiang - Biotech Division: Specialized in monoclonal antibodies, fusion proteins, and biosimilars - Logistics: Centralized distribution hubs with cold chain capabilities ## Certifications and Compliance - US FDA - EU-GMP (Germany, Netherlands approvals) - Japan PMDA - WHO Prequalification (WHO-PQ) - China NMPA (including MAH system participation) - ISO 9001, ISO 14001, OHSAS 18001 ## Customer Testimonials > “CSPC’s NBP capsules have set a new benchmark in ischemic stroke recovery with reliable clinical outcomes and superior patient adherence.” > — Chief Neurologist, Leading Chinese Teaching Hospital > “Their vitamin C exports are of consistent quality, and their logistics performance is world-class.” > — Procurement Director, European Nutraceutical Brand ## Major Achievements - Listed in the Forbes Global 2000 - NBP recognized as National Key New Drug Project by China’s Ministry of Science & Technology - Developed China’s first domestically approved pegfilgrastim biosimilar (Jinyouli) - One of China’s Top 5 exporters of Vitamin C APIs - Holds 100+ DMFs registered globally (US, EU, Japan, India) CSPC Pharmaceutical Group continues to lead China’s pharmaceutical innovation push while expanding its global presence in high-value generics, APIs, and novel therapeutic platforms.
